ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1715925
Sentiment: neutral
Topics: reporting, press-release
TL;DR
IPA files 6-K with press release on Oct 10, 2024. Check Exhibit 99.1 for details.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on October 10, 2024, to report a press release dated October 10, 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The press release itself is included as Exhibit 99.1.
Why It Matters
This filing serves as an official notification to the SEC and investors about the company's reporting status and includes a press release, which may contain material updates.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) primarily containing a press release and confirming reporting status, with no immediate financial disclosures or significant events indicated.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- Kristin Taylor (person) — Signatory for the company
- October 10, 2024 (date) — Date of the press release and filing
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed by ImmunoPrecise Antibodies Ltd. to report a press release dated October 10, 2024, and to confirm its status as a foreign private issuer filing under Form 20-F.
What is included as an exhibit in this filing?
Exhibit 99.1, a Press Release dated October 10, 2024, is included in this filing.
What is the company's principal executive office address?
The company's principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Which annual report form does ImmunoPrecise Antibodies Ltd. file?
ImmunoPrecise Antibodies Ltd. files its annual reports under Form 20-F.
Who signed the report on behalf of ImmunoPrecise Antibodies Ltd.?
Kristin Taylor signed the report on behalf of ImmunoPrecise Antibodies Ltd.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-10-10 09:39:39
Filing Documents
- press_release_oct_10_202.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 16KB
- 0000950170-24-113971.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: October 10, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer